MP Healthcare Venture Management (MPH)
Dr. Moore has extensive healthcare experience in leading biotechnology companies and academic institutions. Jeff is currently President at MP Healthcare Venture Management (MPH), and on the Board of Directors at Diamond Edge Ventures (DEV). MPH is the venture group of Mitsubishi Tanabe Pharma and DEV is the VC group of Mitsubishi Chemical Holdings Corporation. MPH focuses on seed- to Series A investments in companies developing novel therapeutics, platform technologies, and vaccines.
Prior to MPH, Jeff worked as a Kauffman Fellow at Research Corporation Technologies, also focusing on the funding of early stage biotech opportunities.
Previously, Jeff worked in business development at Millennium Pharmaceuticals, evaluating diverse licensing and partnership opportunities. He also held leadership roles at Millennium and coordinated the company's strategic initiative to appropriately deploy technologies across the drug discovery and development process.
Prior to Millennium, Jeff developed novel techniques for infectious disease drug target validation at Scriptgen Pharmaceuticals (now Anadys), was an NSERC research fellow at Harvard Medical School, and was a founding partner of the BioVenture Investment Group. He is the inventor on 5 patents, and has authored numerous peer-reviewed publications.
Education, Personal, and Fellowship
Jeff received his BSc from the University of New Brunswick. He earned his PhD at Oxford, where he elucidated the ability of viruses to overcome host defenses by producing immunosuppressive steroid hormones. He also served on the Oxford Graduate Union and LMH Executive Committee. Jeff received his MBA as a Sloan Fellow at MIT, focusing on finance, strategy and entrepreneurship.
A member of Class 10, Jeff served his fellowship under mentor Shaun Kirkpatrick at Research Corporation Technologies in Tucson, AZ. He is mentor to Laura Tadvalkar (Class 23).